Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drugnews2025-07-31T14:46:10+00:00July 31st, 2025|Endpoints News|
Merck to discontinue drug from Pandion deal; Coya’s IND for ALS drug is delayednews2025-07-30T14:44:27+00:00July 30th, 2025|Endpoints News|
Bausch Health to buy Durect for $63M upfront; Fulcrum’s Ph1b sickle cell datanews2025-07-29T14:58:21+00:00July 29th, 2025|Endpoints News|
Sarepta pays out $100M milestone to Arrowhead; Boehringer signs up to $1B dealnews2025-07-28T15:28:02+00:00July 28th, 2025|Endpoints News|
Everest Medicines raises $200M; Epirium Bio targets $55M Series Bnews2025-07-25T14:42:58+00:00July 25th, 2025|Endpoints News|
LEO Pharma’s eczema cream is approved in the US; Abivax’s $650M offeringnews2025-07-24T15:11:56+00:00July 24th, 2025|Endpoints News|
Arrowhead’s multibillion-dollar deal with Sarepta is still in place; Pharvaris’ $175Mnews2025-07-23T14:45:42+00:00July 23rd, 2025|Endpoints News|
SAB BIO raises $175M; Concentra makes its third acquisition in Julynews2025-07-21T15:04:05+00:00July 21st, 2025|Endpoints News|
Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes news2025-07-18T14:48:10+00:00July 18th, 2025|Endpoints News|
Nicox, Kowa make a deal for glaucoma drug; French techbio raises €15Mnews2025-07-17T14:54:49+00:00July 17th, 2025|Endpoints News|
